Savara Inc. Files Q3 2024 10-Q

TL;DR

Savara's Q3 10-Q is in: check financials for common stock & capital changes.

AI Summary

Savara Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Mast Therapeutics, Inc., reported on its financial status. Key financial data points include information related to common stock, additional paid-in capital, and stock compensation plans for the periods ending September 30, 2023, and September 30, 2024.

Why It Matters

This filing provides investors with an update on Savara Inc.'s financial health and operational status for the third quarter of 2024, crucial for investment decisions.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Savara faces inherent risks related to drug development, regulatory approvals, and market competition, which are reflected in its financial filings.

Key Numbers

• 20240930 — Reporting Period End Date (Indicates the end of the fiscal quarter for this 10-Q filing.)
• 2023-09-30 — Prior Period End Date (Used for comparative financial analysis against the current reporting period.)

Key Players & Entities

• Savara Inc. (company) — Filer of the 10-Q
• Mast Therapeutics, Inc. (company) — Former name of Savara Inc.
• September 30, 2024 (date) — End of reporting period
• September 30, 2023 (date) — Prior period comparison

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share SVRA The Nasdaq Global Se

Filing Documents

• svra-20240930.htm (10-Q) — 1577KB
• svra-ex3_1.htm (EX-3.1) — 56KB
• svra-ex10_2.htm (EX-10.2) — 82KB
• svra-ex10_2.pdf (EX-10.2) — 139KB
• svra-ex10_3.htm (EX-10.3) — 77KB
• svra-ex10_3.pdf (EX-10.3) — 136KB
• svra-ex10_4.htm (EX-10.4) — 65KB
• svra-ex10_4.pdf (EX-10.4) — 147KB
• svra-ex31_1.htm (EX-31.1) — 15KB
• svra-ex31_2.htm (EX-31.2) — 15KB
• svra-ex32_1.htm (EX-32.1) — 11KB
• img199017153_0.jpg (GRAPHIC) — 4KB
• 0000950170-24-125292.txt ( ) — 7710KB
• svra-20240930.xsd (EX-101.SCH) — 1019KB
• svra-20240930_htm.xml (XML) — 1140KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations and Comprehensive Loss 2 Consolidated Statements of Changes in Stockholders' Equity 3 Condensed Consolidated Statements of Cash Flows 5 Notes to Condensed Consolidated Financial Statements 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 21 Item 4.

Controls and Procedures

Controls and Procedures 21 PART II. OTHER INFORMATION 22 Item 1.

Legal Proceedings

Legal Proceedings 22 Item 1A.

Risk Factors

Risk Factors 22 Item 2. Unregistered Shares of Equity Securities and Use of Proceeds 22 Item 3. Defaults Upon Senior Securities 22 Item 4. Mine Safety Disclosures 22 Item 5. Other Information 22 Item 6. Exhibits 22 Exhibit Index 23

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item I. Financ ial Information Savara Inc. a nd Subsidiaries Condensed Consolida ted Balance Sheets (In thousands, except share and per share amounts) September 30, 2024 December 31, 2023 (Unaudited) Assets Current assets: Cash and cash equivalents $ 21,427 $ 26,585 Short-term investments 198,013 135,734 Prepaid expenses and other current assets 6,955 3,628 Total current assets 226,395 165,947 Property and equipment, net 206 270 In-process R&D 11,111 10,960 Other non-current assets 1,105 387 Total assets $ 238,817 $ 177,564 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 4,609 $ 3,504 Accrued expenses and other current liabilities 8,179 7,093 Total current liabilities 12,788 10,597 Long-term liabilities: Long-term debt 26,552 26,348 Other long-term liabilities 128 247 Total liabilities 39,468 37,192 Commitments and contingencies (Note 9) Stockholders' equity: Common stock, $ 0.001 par value, 300,000,000 authorized as of September 30, 2024 and December 31, 2023; 170,842,763 and 138,143,545 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 172 140 Additional paid-in capital 659,084 533,872 Accumulated other comprehensive income (loss) 299 ( 271 ) Accumulated deficit ( 460,206 ) ( 393,369 ) Total stockholders' equity 199,349 140,372 Total liabilities and stockholders' equity $ 238,817 $ 177,564 The accompanying notes are an integral part of these condensed consolidated financial statements. 1 Savara Inc. and Subsidiaries Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share amounts) (Unaudited) For the three months ended September 30, For the nine months ended September 30, 2024 2023 2024 2023 Operating expenses: Rese

View Full Filing

View this 10-Q filing on SEC EDGAR